Qiagen (NYSE:QGEN - Free Report) - Analysts at Zacks Research dropped their Q4 2025 earnings per share (EPS) estimates for shares of Qiagen in a research note issued to investors on Wednesday, February 26th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.63 per share for the quarter, down from their prior forecast of $0.64. The consensus estimate for Qiagen's current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen's Q1 2026 earnings at $0.51 EPS and FY2027 earnings at $2.69 EPS.
A number of other research analysts have also commented on QGEN. UBS Group lowered their price target on Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Robert W. Baird lowered shares of Qiagen from an "outperform" rating to a "neutral" rating and decreased their target price for the company from $52.00 to $42.00 in a research report on Wednesday, February 19th. Baird R W downgraded shares of Qiagen from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 19th. Morgan Stanley reiterated an "equal weight" rating and issued a $46.67 price objective (down from $48.61) on shares of Qiagen in a report on Monday, January 6th. Finally, Jefferies Financial Group reiterated a "buy" rating and set a $52.50 price objective (up previously from $40.83) on shares of Qiagen in a research note on Tuesday, December 10th. Seven analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $47.71.
Read Our Latest Research Report on QGEN
Qiagen Stock Performance
QGEN traded down $0.37 during trading hours on Friday, hitting $37.85. The company's stock had a trading volume of 862,875 shares, compared to its average volume of 1,241,115. The company has a 50-day simple moving average of $42.51 and a 200 day simple moving average of $42.80. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $8.40 billion, a PE ratio of 105.39, a PEG ratio of 2.39 and a beta of 0.36. Qiagen has a fifty-two week low of $37.63 and a fifty-two week high of $49.30.
Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%.
Institutional Trading of Qiagen
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Qiagen in the fourth quarter valued at $95,746,000. Forum Financial Management LP acquired a new stake in shares of Qiagen during the fourth quarter worth $221,000. GF Fund Management CO. LTD. purchased a new stake in shares of Qiagen during the fourth quarter valued at $216,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Qiagen by 6.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 492,302 shares of the company's stock valued at $21,922,000 after purchasing an additional 30,989 shares during the period. Finally, Two Sigma Advisers LP increased its stake in Qiagen by 30.0% in the 4th quarter. Two Sigma Advisers LP now owns 197,112 shares of the company's stock worth $8,777,000 after purchasing an additional 45,505 shares in the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.
Qiagen Company Profile
(
Get Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
See Also
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
